UPDATE: Trillium Therapeutics (TRIL) Halted on LUDP After Plunging 30% on Safety Concerns

November 3, 2016 9:51 AM EDT
Get Alerts TRIL Hot Sheet
Trade TRIL Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
(Updated - November 3, 2016 9:55 AM EDT)

Trillium Therapeutics (NASDAQ: TRIL) slammed following update and now halted on LUDP. Last down 30%.

UPDATE: Downside comes from safety concerns noted in ASH abstracts: "The 0.3 ng/kg dose was associated with reversible, dose-limiting toxicity (DLT) of 2 of 2 points: one pt with G3 elevated ALT/AST and G4 platelet count, and a second pt with G4 platelet count who was transfused."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk, Trading Halts

Add Your Comment